Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: j lawrence who wrote (4647)	6/30/1998 1:17:00 AM
From: chester lee	Read Replies (1) \| Respond to of 7041

<<If a pharmaceutical company was confident that a drug would be approved by the FDA, why would they introduce it into a low-margin market? Why not wait six months to a year and keep the large margins??>> Maybe ZONA is using the mexican market as a field test to act as a barometer of US sales to come, on the long shot that the FDA approves their drug for ED in spite of the small statistical significance when compared to a tasty sugar pill. chester

To: j lawrence who wrote (4647)	6/30/1998 7:41:00 AM
From: Linda Kaplan	Respond to of 7041

J: Zonagen hasn't filed for FDA approval of Vasomax in the US yet, and in best case scenario, meaning FDA approval (which I consider unlikely) could easily wait more than a full year from the time of filing till approval by the FDA for sales in the US. So by having been approved in Mexico they get at least a year and a half of sales income from Mexico before they get any income from the drug from any other source (but SGP). The drawback for them is what is happening. Mexico is becoming a test group and if the drug doesn't work, isn't getting good sales, doesn't make much money for them there, then the investors can see that the drug won't do well, even if approved, in the US. Linda